
    
      This is a prospective, multicentric open-label trial to evaluate the efficacy and safety of
      Iodine-125 brachytherapy together with chemotherapy compared with surgical resection followed
      by concomitant radiochemotherapy in patients with newly diagnosed glioblastoma.

      The primary efficacy outcome was evaluated with progression-free survival (PFS).
    
  